WO2017044843A1 - Full interrogation of nuclease dsbs and sequencing (find-seq) - Google Patents
Full interrogation of nuclease dsbs and sequencing (find-seq) Download PDFInfo
- Publication number
- WO2017044843A1 WO2017044843A1 PCT/US2016/051097 US2016051097W WO2017044843A1 WO 2017044843 A1 WO2017044843 A1 WO 2017044843A1 US 2016051097 W US2016051097 W US 2016051097W WO 2017044843 A1 WO2017044843 A1 WO 2017044843A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- nuclease
- region
- nucleotides
- fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
- C12Q1/6855—Ligating adaptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/301—Endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/319—Exonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/50—Other enzymatic activities
- C12Q2521/501—Ligase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/191—Modifications characterised by incorporating an adaptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/30—Oligonucleotides characterised by their secondary structure
- C12Q2525/301—Hairpin oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
- C12Q2535/122—Massive parallel sequencing
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
Definitions
- Described herein are in vitro methods for defining the genome-wide cleavage specificities of engineered nucleases such as CRISPR-Cas9 Nucleases.
- the present invention is based on the development of sensitive, unbiased methods for genome-wide detection of potential engineered nuclease (e.g., CRISPR-Cas9) off-target cleavage sites from cell type-specific genomic DNA samples.
- the present methods use exonuclease selection of covalently closed DNA molecules to create a population of genomic DNA molecules with very few free DNA ends, as a starting population for cleavage-specific enrichment and sequencing.
- Enrichment of these cleaved fragments enables very sequencing-efficient discovery of in vitro cleaved DNA fragments, in contrast to methods such as Digenome-Seq (Kim et al., Nat Methods. 2015 Mar; 12(3):237-43) that rely on whole-genome sequencing.
- the present in vitro assay detected 100% of off-target cleavage sites detected by the in- cell GUIDE-seq assay at the VEGFA site target site used as a test case and described in Tsai et al., Nat Biotechnol. 2015 Feb;33(2): 187-97 (in other words, the present in vitro assay detects a superset of GUIDE-seq detected cleavage sites).
- Described herein are methods of enzymaticallv preparing a l ibrary of DNA fragments without DNA double-stranded breaks (DSBs) (the terms “breaks” and “cleavage” are used herein interchangeably) by ligation of stem-loop or hairpin adapters followed by exonuclease selection, and for detecting nuclease-induced cleavage of this enzymatically purified library of covalently closed DNA fragments by sequencing.
- these two methods comprise a strategy for efficiently mining for nuclease-induced cleavage sites in complex mixtures of DNA.
- the methods can include creating a population of molecules without ends, treating that population with a nuclease, and finding molecules in this population that have newly created ends as a result of nuclease-induced cleavage.
- the invention provides methods for preparing a library of covalently closed DNA fragments.
- the methods include providing DNA, e.g., gDNA from a cell type or organism of interest; optionally randomly shearing the DNA to a defined average length, e.g., an average length of about 200-1000 bps, e.g., about 500 bps, to provide a population of DNA fragments; preparing the fragments for end- ligation, e.g., by end-repairing and then A -tailing the sheared DNA; ligating a first hairpin adapter comprising at least a single deoxyuridme (uracil) and a first primer site compatible for use in PCR priming and/or sequencing, e.g., next generation sequencing (NGS) to the ends of the fragments, to prepare a population of ligated fragments; contacting the ligated fragments with a nuclease that induces double stranded breaks; and purifying the ligated fragments using an ex
- the methods can also include contacting the library of covalently closed DNA fragments with a nuclease to induce site-specific cleavage; ligating a second hairpin adapter comprising at least a single deoxyuridine and a second primer site compatible for use with the first primer site in PCR priming and/or sequencing; contacting the library with an enzyme, e.g., uracil DNA glycosylase (UDG) and/or endonuclease VIII, a DNA glycosylase-lyase, to nick the DNA at the deoxyuridine; and sequencing those fragments having a first and second hairpin adapter.
- an enzyme e.g., uracil DNA glycosylase (UDG) and/or endonuclease VIII, a DNA glycosylase-lyase
- the methods can include providing DNA, e.g., gDNA from a cell type or organism of interest; randomly shearing the DNA to a defined average length, e.g., an average length of about 200-1000 bps, e.g., about 100-500 bps; optionally end- repairing and then A -tailing the sheared DNA; ligating a first single-tailed hairpin adapter, preferably comprising a first region, e.g., of about 10-20, e.g., 12 nucleotides; a second region, e.g., of about 45-65, e.g., 58 nucleotides, that forms one or more hairpin loops and comprises a first primer site compatible for use in PGR priming and/or sequencing, e.g., next generation sequencing (NGS); and
- NGS next generation sequencing
- coli Exol, PlasmidSafeTM ATP -dependent exonuciease sufficient to degrade any DNA molecules that lack the first (e.g., 5') single-tailed hairpin adapter ligated to both of their ends; treating the sample with a nuclease to induce site-specific cleavage (e.g., of on- and/or off-target sites, e.g., to induce blunt or staggered/overhanging ends) optionally end-repairing and then A- tailing the resulting ends; ligating a second (e.g., 3') single-tailed hairpin adapter comprising a first region of about 10-20, e.g., 15 nucleotides; a second region of about 40-60, e.g., 48, nucleotides that forms one or more hairpin loops and comprises a second primer compatible for use with the first primer site in PGR priming and/or sequencing, e.g., next generation sequencing (NGS); and a third region of about 10- 20,
- the methods include contacting the library with uracil DNA glycosylase (UDG) and/or endonuclease VITI, a DNA glycosylase-lyase to nick the DNA at the deoxyuridine; and sequencing those fragments bearing a first and a second hairpin adapter.
- UDG uracil DNA glycosylase
- VITI endonuclease VITI
- the methods include providing DNA, e.g., gDNA from a cell type or organism of interest: randomly shearing the DNA to a defined average length, e.g., an average length of about 200-1000 bps, e.g., about 500 bps; optionally end-repairing and then A-tailing the sheared DNA; ligating a first single-tailed hairpin adapter, preferably comprising a first region, e.g., of about 10-20, e.g., 12 nucleotides; a second region, e.g., of about 45-65, e.g., 58 nucleotides, that forms one or more hairpin loops and comprises a first primer site compatible for use in PCR priming and/or sequencing, e.g., next generation sequencing (NGS); and a
- coli Exol PlasrnidSafeTM ATP-dependent exonuclease
- treating the sample with a nuclease to induce site-specific cleavage the DNA e.g., toarrive on- and/or off-target cleavage sites; optionally end- repairing and then A-tailing the resulting cleaved ends; ligating a second (e.g., 3') single-tailed hairpin adapter comprising a first region of about 10-20, e.g., 15 nucleotides; a second region of about 40-60, e.g., 48, nucleotides that forms one or more hairpin loops and comprises a second primer compatible for use with the first primer site in PCR priming and/or sequencing, e.g., next generation sequencing
- NGS nucleotide
- a third region of about 10-20 e.g., 16 nucleotides (e.g., one longer than the first region) that is complementary to the first region, and that also contains a single deoxyuridine nucleotide between the second and third regions, to create a population wherein the DNA fragments that were cleaved by the nuclease have the first and second hairpin adapters ligated to their respective ends; thereby preparing a library of fragments comprising nuclease-induced double stranded breaks in the DNA, e.g., wherein one end was created by a nuclease-induced double stranded break in the DN A; contacting the library with uracil DNA glycosyiase (UDG) and/or
- UDG uracil DNA glycosyiase
- endonuclease VIII a DNA glycosylase-lyase to nick the DNA at the deoxyuridine; and sequencing those fragments bearing a first and a second hairpin adapter; thereby detecting DSBs induced by the nuclease.
- the engineered nuclease is selected from the group consisting of meganucleases, MegaTALs, zinc-finger nucleases, transcription activator effector-like nucleases (TALEN), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas RNA-guided nucleases (CRISPR/Cas RGNs).
- treating the sample with a nuclease to induce site- specific cleavage comprises contacting the sample with a Cas9 nuclease complexed with a specific guide RNA (gRNA).
- gRNA specific guide RNA
- the methods include, for each of the plurality of guide RNAs: providing gDNA from a cell type or organism of interest; randomly shearing the gDNA to a defined average length, e.g., an average length of about 200-1000 bps, e.g., about 500 bps; optionally end-repairing and then A -tailing the sheared gDNA; ligating a first single-tailed hairpin adapter, preferably comprising a first region, e.g., of about 10-20, e.g., 12 nucleotides; a second region, e.g., of about 45-65, e.g., 58 nucleotides, that forms one or more hairpin loops and comprises a first primer site compatible for use in PGR priming and/or sequencing, e.g., next generation sequencing (
- a Cas9 nuclease compatible with the guide RNA to induce site-specific cleavage (e.g., of on- and/or off-target sites, e.g., to produce blunt or staggered/overhanging ends); optionally end- repairing and then A-tailing the resulting cleaved ends; ligating a second (e.g., 3') single-tailed hairpin adapter comprising a first region of about 10-20, e.g., 15 nucleotides; a second region of about 40-60, e.g., 48, nucleotides that forms one or more hairpin loops and comprises a second primer compatible for use with the first primer site in PCR priming and/or sequencing, e.g., next generation sequencing (NGS); and a third
- endonuclease VIII a DNA glycosylase-lyase to nick the DNA at the deoxyuridine; and sequencing those fragments bearing a first and a second hairpin adapter, thereby detecting DSBs induced by the nuclease in each sample; optionally identifying whether each DSB is on-target or off-target; comparing the DSBs induced by the nuclease in each sample; and determining which of the plurality of guide RNAs induced the fewest off-target DSBs.
- the DNA is isolated from, a mammalian, plant, bacterial, or fungal cell (e.g., gDNA).
- the DNA is synthetic.
- the engineered nuclease is a TALEN, zinc finger, meganuciease, megaTAL, or a Cas9 nuclease.
- the engineered nuclease is a Cas9 nuclease
- the method also includes expressing in the cells a guide RNA that directs the Cas9 nuclease to a target sequence in the genome.
- the primer site in the first or second hairpin adapter comprises a next generation sequencing primer site, a randomized DNA barcode or unique molecular identifier (UMI).
- UMI unique molecular identifier
- the present methods have several advantages.
- the present methods are in vitro; in contrast, GUTDE-seq is cell-based, requiring the introduction of double stranded oligodeoxynucleotides (dsODN) as well as expression or introduction of nuclease or nuclease-encoding components into cells.
- dsODN double stranded oligodeoxynucleotides
- Not all cells will allow the introduction of dsODNs and/or nuclease or nuclease-encoding components, and these reagents can be toxic in some cases.
- a surrogate cell type might be used, but cell-specific effects might not be detected.
- the present methods do not require delivery of the dsODN, nuclease, or nuclease-encoding components into a cell, are not influenced by chromatin state, do not create toxicity issues, and enable interrogation of specific cellular genomes by cleavage of genomic DN A that is obtained from the cell-type of interest.
- all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
- FIGS 1A-B Overview of an exemplary in vitro assay for genome-wide identification of CRISPR/Cas9 cleavage sites from, complex mixtures of DNA called FIND-seq (Full Interrogation of Nuclease DSBs).
- FIND-seq Full Interrogation of Nuclease DSBs.
- Genomic DNA is isolated from human cells and sheared to an average of -500 bp using a Covaris S220 AFA instrument. Sheared DNA is end-repaired, A-taiied, and ligated with a 5' single-tailed hairpin adapter containing a single deoxyuradine. Successful, ligation of the hairpin adapter to both ends of the DNA fragments will result in covendedly closed DNA with no free end.
- Lambda Exonuclease and E. coli Exol or PiasmidSafe ATP -dependent exonuclease can then be used to dramatically reduce the background of DNA with free ends, leaving a predominantly uniform population of covendedly closed DNA molecules.
- Cas9 cleavage of adapter-ligated gDNA will produce ends with free 5' phosphates for the ligation of a second 3' single-tailed hairpin adapter that also contains a single uracil base.
- Treatment with USER, enzyme mixture and PCR enriches for DNA molecules that have been ligated with both 5' and 3' single-tailed adapters.
- the arrow indicates the predicted cut site and data is shown for 3 target sites in the VEGFA locus.
- a sample treated with Streptococcus pyogenes Cas9 compiexed with EMX1 gRNA is also shown as a negative control, (b) Visualization of example 'off-target' genomic region
- Bidirectionaliy mapping reads with 'uniform' ends can be observed in tins region and are typical of sites detected by this in vitro assay. Reads generally start within 1-bp of the predicted cut-site and originate outward in both directions from this position.
- Figures 3A-D Analysis of FIND-seq in vitro cleavage selection assay results using different exonuclease treatment conditions, (a) Mapped read counts at genome- wide in vitro cleavage assay detected sites for a under different exonuclease treatments, (b) Number of sites detected by genome-wide in vitro cleavage assay with different exonuclease treatments, (c) Average read counts at genome-wide in vitro cleavage assay detected sites under different exonuclease treatments, (d) Percentage of GUTDE-seq detected sites that are detected by genome-wide in vitro cleavage assay. Note there are three conditions where 100% of GUIDE-seq sites are detected using the simple in vitro assay.
- Figure 4 Venn diagram of overlap between GUIDE-seq and FIND-seq genomic in vitro cleavage assay performed with 1 hour of lambda exonuclease and E. coli exonuclease I, and 1 hour of PlasmidSafe exonuclease treatment at the VEGFA target site 1. In tins condition, 100% of GUIDE-seq sites are also detected with the in vitro assay.
- Figures 5A-B Analysis of FIND-seq genomic in vitro cleavage assay testing the adapter ligation order with different exonuclease treatment conditions. The condition that detected the highest number of sites was 1 hr PlasmidSafe, 1 hr Lambda exonuclease/E. Coli exonuclease I treatment, with the 3' adapter added first.
- CRISPR-Cas9 nucleases An important consideration for the therapeutic deployment of CRJSPR-Cas9 nucleases is having robust, comprehensive, unbiased, and highly sensitive methods for defining their off-target effects. Recently, a number of methods for defining the genome-wide off-target effects of CRISPR-Cas9 and other customizable nucleases have been described.
- the GUIDE-seq method which relies on uptake of a short double-stranded oligonucleotide "tag" into nuclease-induced DSBs in living cells, has been shown to define off-target sites on a genome-wide scale, identifying sites that are mutagenized with frequencies as low as 0.1% of the time in a population of cells (Tsai et a!., Nat Biotechnol. 2015).
- Other cell-based methods for defining nuclease-induced off -target breaks include a method that maps translocation fusions to the on-target site and another that relies on uptake of integration-deficient lenti virus (IDLV) genomes into sites of DSBs.
- IDLV integration-deficient lenti virus
- cell-based methods for off-target determination have a number of limitations including: (i) a requirement to be able to introduce both the nuclease components and a tag such as the dsODN or IDLV genome into cells; (2) biological selection pressures that might favor or disfavor the growth of cells harboring certain types of off-target mutations; and/or (3) the potential confounding effects of cell -type-specific parameters such as chromatin, DNA methylation, gene expression, and nuclear architecture on nuclease off-target activities/effects.
- in vitro methods using purified genomic DNA provide an attractive alternative because they would sidestep these various limitations of cell-based approaches.
- in vitro methods face the challenge that isolated genomic DNA is by experimental necessity randomly sheared (or broken) into smaller pieces. This poses a challenge because it is not easy to differentially identify DSBs induced by shearing from those induced by treatment of the genomic DNA in vitro by nucleases.
- the recently described Digenome attempted to use alignment of common ends induced by nucleases in genomic sequence but the signal for this type of event can be challenging to discern relative to the background of random DSBs from shearing of genomic DNA induced during genomic DNA isolation and by deliberate shearing of the DNA to smaller size pieces required for DNA sequencing methods.
- genomic DNA from a cell type or organism of interest is randomly sheared to a defined average length .
- an average length of 500 bps worked well for subsequent next-generation sequencing steps; however, shorter or longer lengths can also be used.
- the random broken ends of this genomic DNA are end repaired (i.e., the random, overhanging ends are filled m/blunted, e.g., using T4 polymerase, Klenow fragment, and T4 Polynucleotide
- A-tailed hairpin adapter preferably bearing a 5' end next-generation sequencing primer site, that also contains a single deoxyuridine nucleotide at a specific position ( Figure IB) and a I -nucleotide (thymidine) overhang at the 3 ' end; hereafter this adapter is referred to as the "5' single-tailed hairpin adapter” or simply "5' hairpin adapter”.
- the sample is then treated with one or more exonucleases (e.g., bacteriophage lambda exonuclease, E. coli Exol, PlasmidSafeTM ATP -dependent exonuclease) that degrade any DNA molecules that have not had the 5' single-tailed hairpin adapter ligated to both of their ends.
- exonucleases e.g., bacteriophage lambda exonuclease, E. coli Exol, PlasmidSafeTM ATP -dependent exonuclease
- the collection of molecules is then treated to induce blunt-end cuts, e.g., with a Cas9 nuclease complexed with a specific guide RNA (gRNA).
- gRNA specific guide RNA
- the resulting nuclease-induced blunt ends are A-tailed and then a second hairpin adapter bearing a 3 ' end next-generation sequencing primer site and that also contains a single deoxyuridine nucleotide at a specific position is ligated to these ends; this adapter is also referred to herein as the "3' single-tailed hairpin adapter” or simply ' " 3 " hairpin adapter”.
- the present methods can be used to prepare libraries of fragments for next generation sequencing, e.g., to identify guideRNA/Cas9 combinations that induce the most specific DSBs (e.g., that have the fewest off-target effects), e.g., for therapeutic or research purposes.
- the present methods include the use of non-naturally occurring 3' and 5' single-tailed hairpin adapters.
- the hairpin adapters include (from 5' to 3') a first region, e.g., of about 10-20, e.g., 12 or 15, nucleotides; a second region, e.g., of about 45-65, e.g., 58 or 48, nucleotides that fonns one or more hairpi n loops and includes a sequence compatible for use in PGR priming and/or sequencing, e.g., next generation sequencing (NGS); and a third region, e.g., of about 10-20, e.g., 13 or 16, nucleotides that is complementary to the first region.
- the lengths of the first, second and third regions can vary' depending on the NGS method selected, as they are dependent on the sequences that are necessary for priming for use with the selected NGS platform.
- the hairpin adapters include at least one, preferably only one, uracil that allows the adaptor to be opened by Uracil DNA glycosylase (UDG) and Endonuciease VIII, a DNA glycosylase-lyase, e.g., the USER (Uracil-Specific Excision Reagent) Enzyme mixture (New England BioLabs).
- UDG Uracil DNA glycosylase
- Endonuciease VIII a DNA glycosylase-lyase
- the UDG catalyzes the excision of uracil bases to form an abasic site but leave the phosphodiester backbone intact (see, e.g., Lindhal et al., J. Biol. Chem.. 252:3286-3294 (1977); Lindhal, Annu. Rev. Biochem. 51 :61-64 (1982)).
- Endonuciease VIII breaks the phosphodiester backbone at the 3 ' and 5 ' sides of the abasic site (see, e.g., Melamede et al., Biochemistry 33: 1255- 1264 (1994); Jiang et a!., J. Biol. Chem. 272:32230-32239 (1997)). This combination generates a single nucleotide gap at the location of a uracil.
- the uracil in the 5' single-tailed hairpin adapters the uracil is placed at or within 1, 2, 3, or 4 nucleotides of the end of the first region and the beginning of the second region, and in the 3' single-tailed hairpin adapters the uracil is placed at or within 1, 2, 3, or 4 nucleotides of the end of the first region and the beginning of the second region.
- ail parts of the hairpin adapters are preferably orthologous to the genome of the cell (i.e., are not present in or complementary to a sequence present in, i.e., have no more than 10%, 20%, 30%, 40%, or 50% identity to a sequence present in, the genome of the cell).
- the hairpin adapters can preferably be between 65 and 95 nts Song, e.g., 70-90 nts or 75-85 nts long.
- Each of the 5' and 3' single-tailed hairpin adapters should include a primer site that is a randomized DNA barcode (e.g., SHAPE-SEQ, Lucks et al., Proc Natl Acad Sci U S A 108: 11063-11068), unique molecular identifier (UMI) (see, e.g., Kivioja et al. Nature Methods 9, 72-74 (2012); Islam, et al.. Nature Methods 11, 163-166 (2014); Karlsson et al., Genomics. 2015 Mar; 105(3): 150-8), or unique PCR priming sequence and/or unique sequence compatible for use in sequencing (e.g., NGS).
- a randomized DNA barcode e.g., SHAPE-SEQ, Lucks et al., Proc Natl Acad Sci U S A 108: 11063-11068
- UMI unique molecular identifier
- the sequence compatible for use in sequencing can be selected for use with a desired sequencing method, e.g., a next generation sequencing method, e.g., lilumma, Ion Torrent or library preparation method like Roche/454, lllumina Solexa Genome Analyzer, the Applied Biosystems SOLiDTM system, Ion TorrentTM semiconductor sequence analyzer, PacBio® real-time sequencing and HelicosTM Single Molecule Sequencing (SMS).
- a desired sequencing method e.g., a next generation sequencing method, e.g., lilumma, Ion Torrent or library preparation method like Roche/454, lllumina Solexa Genome Analyzer, the Applied Biosystems SOLiDTM system, Ion TorrentTM semiconductor sequence analyzer, PacBio® real-time sequencing and HelicosTM Single Molecule Sequencing (SMS).
- a desired sequencing method e.g., a next generation sequencing method, e.g., lilumma
- kits are commercially available for preparing DNA for NGS, including the ThruPLEX DNA-seq Kit (Rubicon; see U.S. Patents 7,803,550; 8,071,312; 8,399,199; 8,728,737) and NEBNext® (New England BioLabs; see e.g., U.S. patent 8,420,319)). Exemplary sequences are shown in Table A, below.
- the hairpin adapters include a restriction enzyme recognition site, preferably a site that is relatively uncommon in the genome of the cell.
- the hairpin adapters are preferably modified; in some embodiments, the 5 ' ends of the hairpin adapters are phosphorylated. In some embodiments, the hairpin adapters are blunt ended. In some embodiments, the hairpin adapters include a random variety of 1, 2, 3, 4 or more nucleotide overhangs on the 5' or 3 ' ends, or include a single T at the 5' or 3' end.
- the hairpin adapters can also include one or more additional modifications, e.g., as known in the art or described in PCT/US2011/060493.
- the hairpin adapters is biotinylated.
- the biotin can be anywhere internal to the hairpin adapters (e.g., a modified thymidine residue (Biotin-dT) or using biotin azide), but not on the 5' or 3' ends. This provides an alternate method of recovering fragments that contain the FIND-seq hairpin adapters.
- these sequences are retrieved and identified by PGR, in this approach they are physically pulled down and enriched by using the biotin, e.g., by binding to streptavidin-coated magnetic beads, or using solution hybrid capture; see, e.g., Gnirke et al., Nature Biotechnology 27, 182 - 189 (2009).
- the adapters can be added in either order, i.e., 5' adapter then 3' adapter, or 3 ' adapter then 5 ' adapter.
- the order may be optimized depending on the exonuclease treatment used, e.g., for Lambda exonuclease, which is a highly processive 5' -> 3' exonuclease, w here adding the 5' adapter second may be advantageous.
- CRISPR Gas RNA-guided nucleases
- RGN Gas RNA-guided nucleases
- Meganucleases are sequence-specific endonucleases originating from a variety of organisms such as bacteria, yeast, algae and plant organelles. Endogenous meganucleases have recognition sites of 12 to 30 base pairs; customized DNA binding sites with 18bp and 24bp-long meganuclease recognition sites have been described, and either can be used in the present methods and constructs. See, e.g., Silva, G., et al., Current Gene Therapy, 1 1 : 11-27, (2011); Arnould et al., Journal of Molecular Biology, 355:443-58 (2006); Arnould et al.. Protein Engineering Design & Selection, 24: 27-31 (2011); and Stoddard, Q. Rev, Biophys. 38, 49 (2005); Gnzot et al., Nucleic Acids Research, 38:2006-18 (2010).
- CRISPR clustered, regularly interspaced, short palindromic repeats
- Cas CRISPR-associated systems
- gRNA engineered guide RNA
- PAM protospacer adjacent motif
- the present system utilizes a wild type or variant Cas9 protein from S. pyogenes or Staphylococcus aureus, either as encoded in bacteria or codon-optimized for expression in mammalian cells.
- the guide RNA is expressed in the cell togetiier with the Cas9. Either the guide RNA or the nuclease, or both, can be expressed transiently or stably in the cell.
- TAL effectors of plant pathogenic bacteria in the genus Xanthomonas play important roles in disease, or trigger defense, by binding host DNA and activating effector-specific host genes. Specificity depends on an effector-variable number of imperfect, typically -33-35 amino acid repeats. Polymorphisms are present primarily at repeat positions 12 and 13, which are referred to herein as the repeat variable- diresidue (RVD).
- RVDs of TAL effectors correspond to the nucleotides in their target sites in a direct, linear fashion, one RVD to one nucleotide, with some degeneracy and no apparent context dependence.
- the polymorphic region that grants nucleotide specificity may be expressed as a triresidue or triplet.
- Each DNA binding repeat can include a RVD that determines recognition of a base pair in the target DNA sequence, wherein each DNA binding repeat is responsible for recognizing one base pair in the target DNA sequence.
- the RVD can comprise one or more of: HA for recognizing C; ND for recognizing C; HI for recognizing C: HN for recognizing G; NA for recognizing G; SN for recognizing G or A; YG for recognizing T; and NK for recognizing G, and one or more of: HD for recognizing C; NG for recognizing T; NI for recognizing A; NN for recognizing G or A; N S for recognizing A or C or G or T; N* for recognizing C or T, wherein * represents a gap in the second position of the RVD; HG for recognizing T; H* for recognizing T, wherein * represents a gap in the second position of the RVD; and IG for recognizing T.
- TALE proteins may be useful in research and biotechnology as targeted chimeric nucleases that can facilitate homologous recombination in genome engineering (e.g., to add or enhance traits useful for biofuels or biorenewables in plants). These proteins also may be useful as, for example, transcription factors, and especially for therapeutic applications requiring a very high le vel of specificity such as therapeutics against pathogens (e.g., viruses) as non-limiting examples.
- pathogens e.g., viruses
- MegaTALs which are a fusion of a meganuclease with a TAL effector; see, e.g., Boissel et al, Nucl. Acids Res. 42(4):2591-2601 (2014); Boissel and Scharenberg, Methods Mol Biol.
- Zinc finger proteins are DNA-binding proteins that contain one or more zinc fingers, independently folded zinc-containing mini-domains, the structure of which is well known in the art and defined in, for example, Miller et al, 1985, EMBO J, 4: 1609; Berg, 1988, Proc. Natl. Acad. Sci. USA, 85:99; Lee et al, 1989, Science. 245:635; and King, 1993, Gene, 135:83.
- Crystal structures of the zinc finger protein Zif268 and its variants bound to DNA show a semi-conserved pattern of interactions, in which typically three amino acids from the alpha-helix of the zinc finger contact three adjacent base pairs or a ' " subsite" in the DNA (Pavletich et al., 1991, Science, 252:809; Elrod-Erickson et al, 1998, Structure, 6:451).
- the crystal structure of Zif268 suggested that zinc finger DNA-binding domains might function in a modular manner with a one-to-one interaction between a zinc finger and a three-base-pair "subsite" m the DNA sequence.
- multiple zinc fingers are typically linked together in a tandem array to achieve sequence-specific recognition of a contiguous DNA sequence (Klug, 1993, Gene 135:83).
- Such recombinant zinc finger proteins can be fused to functional domains, such as transcriptional activators, transcriptional repressors, methylation domains, and nucleases to regulate gene expression, alter DNA metliylation, and introduce targeted alterations into genomes of model organisms, plants, and human cells (Carroll, 2008, Gene Ther., 15: 1463-68; Cathomen, 2008, Mol. Ther., 16: 1200-07; Wu et al., 2007, Cell. Mol. Life Sci , 64:2933-44).
- functional domains such as transcriptional activators, transcriptional repressors, methylation domains, and nucleases to regulate gene expression, alter DNA metliylation, and introduce targeted alterations into genomes of model organisms, plants, and human cells
- module assembly One existing method for engineering zinc finger arrays, known as "modular assembly,” advocates the simple joining together of pre-selected zinc finger modules into arrays (Segal et al, 2003, Biochemistry, 42:2137-48; Beerli et al, 2002, Nat. Biotechnol., 20: 135-141; Mandell et al, 2006, Nucleic Acids Res, 34:W516-523; Carroll et al., 2006, Nat. Protoc. 1 : 1329-41; Liu et al., 2002, J. Biol. Chem.,
- the zinc finger arrays are described in, or are generated as described in, WO 2011/017293 and WO 2004/099366. Additional suitable zinc finger DBDs are described in U.S. Pat. Nos. 6,511,808, 6,013,453, 6,007,988, and 6,503,717 and U.S. patent application 2002/0160940.
- the methods described herein can be applied to any double stranded DNA, e.g., genomic DNA isolated from any cell, artificially created populations of DNAs, or any other DNA pools, as it is performed in vitro.
- double stranded DNA e.g., genomic DNA isolated from any cell, artificially created populations of DNAs, or any other DNA pools, as it is performed in vitro.
- sequencing includes any method of determining the sequence of a nucleic acid. Any method of sequencing can be used in the present methods, including chain terminator (Sanger) sequencing and dye terminator sequencing.
- chain terminator Sanger
- dye terminator Sanger
- Next Generation Sequencing NGS
- a high- throughput sequencing technology that performs thousands or millions of sequencing reactions in parallel, is used.
- the different NGS platforms use varying assay chemistries, they all generate sequence data from a large number of sequencing reactions run simultaneously on a large number of templates. Typically, the sequence data is collected using a scanner, and then assembled and analyzed bioinformatically.
- sequencing reactions are performed, read, assembled, and analyzed in parallel; see, e.g., US 20140162897, as well as Voelkerding et al, Clinical Chem., 55: 641 -658, 2009; and MacLean et a!., Nature Rev. Microbiol, 7: 287-296 (2009).
- Some NGS methods require template amplification and some that do not.
- Amplification-requiring methods include pyrosequencing (see, e.g., U.S. Pat. Nos. 6,210,89 and 6,258,568; commercialized by Roche); the Solexa/lllumina platform (see, e.g., U.S. Pat. Nos. 6,833,246, 7,115,400, and 6,969,488); and the Supported Oligonucleotide Ligation and Detection (SOLID) platform (Applied Biosvstems; see, e.g., U.S. Pat. Nos. 5,912,148 and 6, 130,073).
- Methods that do not require amplification include nanopore sequencing, HeliScope (U.S. Pat.
- hybridization-based sequence methods or other high-throughput methods can also be used, e.g., microarray analysis, NANOSTRING, ILLUMINA, or other sequencing platforms.
- kits for use in the methods described herein can include one or more of the following: 5' single-tailed hairpin adapters; 3' single- tailed hairpin adapters; reagents and/or enzymes for end repair and A tailing (e.g., T4 polymerase, Klenow fragment, T4 Polynucleotide Kinase (PNK), and/or Taq DNA Polymerase): exonuclease; uracil DNA glycosylase (UDG) and/or endonuclease VIII, a DNA glycosylase-iyase, e.g., the USER (Uracil-Specific Excision Reagent) Enzyme mixture (New England BioLabs); purified cas9 protein; guideRNA (e.g., control gRNA); gDNA template (e.g., control gDNA template); and instructions for use in a method described herein.
- a tailing e.g., T4 polymerase, Klenow fragment, T4 Polynu
- the sequences in CAPS are dual-index barcodes (for demultiplexing samples) in the Illumina Truseq library preparation system.
- the * represents a phosphorothioate linkage.
- genomic DNA from a cell type or organism of interest is randomly sheared to a defined average length.
- an average length of 500 bps works well for subsequent next-generation sequencing steps. The random broken ends of this genomic DNA are end repaired and then A-tailed.
- this adapter is also referred to herein as the "5' single-tailed hairpin adapter".
- the sample is then treated with one or more exonucleases (e.g., bacteriophage lambda exonuclease, E. coli Exol, PlasmidSafe ATP-dependent exonuclease), which degrades any DNA molecules that have not had the 5' single-tailed hairpin adapter ligation to both of their ends.
- exonucleases e.g., bacteriophage lambda exonuclease, E. coli Exol, PlasmidSafe ATP-dependent exonuclease
- the collection of molecules is then treated with Cas9 nuclease complexed with a specific guide RNA (gRNA).
- gRNA specific guide RNA
- the resulting nuclease-induced blunt ends are A- tailed and then a second hairpin adapter bearing a 3' end next-generation sequencing primer site and that also contains a single deoxyuridine nucleotide at a specific position is ligated to these ends; this adapter is also referred to herein as the "3' single-tailed hairpin adapter".
- the only DNA fragments that should have a 5 " and a 3' single-tailed hairpin adapter ligated to their ends are those that were cleaved by the nuclease.
- the adapters can be added in any order. Following treatment by the USER enzyme mixture, which nicks DNA wherever a deoxyuridine is present, only those fragments bearing the two types of adapters can be sequenced.
- nuclease cleavage will have multiple bi- direction reads originating at the site of the nuclease-induced DSB, typically within a nucleotide of the cut site ( Figures 2A and 2B). As nuclease-induced cleavage produces 'uniform' ends, in contrast to the staggered ends that results from random physical shearing of DNA, these sites can be simply bioinformatically identified by their signature uniform read alignments.
- Table 1 List of sgRNA target sites tested with in vitro cleavage selection assay.
- VEGFA site2 U20S GACCCCCTCCACCCCGCCTCNGG 20
- a critical parameter for optimization of the present method was the efficiency of degradation of linear DNA fragments following the ligation of the first 5' single- tailed hairpin adapter. Indeed, without wishing to be bound by theory, most of the ' " background" reads mapped throughout the genome may be due to incomplete digestion of unligated DNA at this step, thereby leaving ends to which the second 3' single tailed hairpin adapter can be ligated.
- the methods were further optimized by testing various kinds and numbers of exonucleases and lengths of incubation to find an optimal treatment method.
- three treatments consistently yielded the highest number of reads and sites and also found 100% of the off-target sites identified by matched GUIDE-seq experiments with the same gRNAs: 1 hour PlasmidSafe treatment, two serial 1 hour PlasmidSafe treatments, and 1 hour of Lambda exonuclease treatment followed by 1 hour of PlasmidSafe treatment-
- the methods were again performed using CRISPR-Cas9 nuclease and a gRNA targeted to VEGFA site 1. This experiment yielded a larger number of off-target sites.
- Reasons for this might include greater sensitivity of this in vitro method, negative biological selection against certain off-target mutations when practicing GUIDE-seq in cells, and/or negative effects of chromatin, DNA methylation, and gene expression on the activity of nucleases in cells.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201680065929.XA CN108350453A (en) | 2015-09-11 | 2016-09-09 | The rough complete querying of nuclease DSB and sequencing (FIND-SEQ) |
JP2018513347A JP2018530536A (en) | 2015-09-11 | 2016-09-09 | Full verification and sequencing of nuclease DSB (FIND-seq) |
EP16845183.9A EP3347467B1 (en) | 2015-09-11 | 2016-09-09 | Full interrogation of nuclease dsbs and sequencing (find-seq) |
AU2016319110A AU2016319110B2 (en) | 2015-09-11 | 2016-09-09 | Full interrogation of nuclease DSBs and sequencing (FIND-seq) |
KR1020187009641A KR20180043369A (en) | 2015-09-11 | 2016-09-09 | Complete call and sequencing of nuclease DSB (FIND-SEQ) |
CA3000816A CA3000816A1 (en) | 2015-09-11 | 2016-09-09 | Full interrogation of nuclease dsbs and sequencing (find-seq) |
IL257955A IL257955A (en) | 2015-09-11 | 2018-03-07 | Full interrogation of nuclease dsbs and sequencing (find-seq) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562217690P | 2015-09-11 | 2015-09-11 | |
US62/217,690 | 2015-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017044843A1 true WO2017044843A1 (en) | 2017-03-16 |
Family
ID=58236806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/051097 WO2017044843A1 (en) | 2015-09-11 | 2016-09-09 | Full interrogation of nuclease dsbs and sequencing (find-seq) |
Country Status (9)
Country | Link |
---|---|
US (2) | US9988674B2 (en) |
EP (1) | EP3347467B1 (en) |
JP (1) | JP2018530536A (en) |
KR (1) | KR20180043369A (en) |
CN (1) | CN108350453A (en) |
AU (1) | AU2016319110B2 (en) |
CA (1) | CA3000816A1 (en) |
IL (1) | IL257955A (en) |
WO (1) | WO2017044843A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108753923A (en) * | 2018-06-04 | 2018-11-06 | 广州微芯生物科技有限公司 | A kind of method building the sequencing library that methylates and corresponding joint sequence and kit |
CN108753922A (en) * | 2018-06-04 | 2018-11-06 | 广州微芯生物科技有限公司 | A kind of method building transcript profile sequencing library and corresponding joint sequence and kit |
CN108753921A (en) * | 2018-06-04 | 2018-11-06 | 广州微芯生物科技有限公司 | A kind of method building gene order-checking library and corresponding joint sequence and kit |
WO2019224560A1 (en) * | 2018-05-24 | 2019-11-28 | Oxford Nanopore Technologies Limited | Method |
EP3500669A4 (en) * | 2016-08-16 | 2020-01-22 | The Regents of the University of California | Method for finding low abundance sequences by hybridization (flash) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10435685B2 (en) * | 2014-08-19 | 2019-10-08 | Pacific Biosciences Of California, Inc. | Compositions and methods for enrichment of nucleic acids |
AU2016319110B2 (en) | 2015-09-11 | 2022-01-27 | The General Hospital Corporation | Full interrogation of nuclease DSBs and sequencing (FIND-seq) |
US11661624B2 (en) * | 2017-03-30 | 2023-05-30 | Pioneer Hi-Bred International, Inc. | Methods of identifying and characterizing gene editing variations in nucleic acids |
CN111278450B (en) | 2017-08-23 | 2024-04-09 | 通用医疗公司 | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
US11725228B2 (en) | 2017-10-11 | 2023-08-15 | The General Hospital Corporation | Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies |
SG11201913654QA (en) | 2017-11-15 | 2020-01-30 | 10X Genomics Inc | Functionalized gel beads |
AU2019256287A1 (en) | 2018-04-17 | 2020-11-12 | The General Hospital Corporation | Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents |
CN113330122A (en) * | 2018-11-16 | 2021-08-31 | 德皮克斯公司 | In vitro isolation of optimized nucleic acids using site-specific nucleases |
US20220127661A1 (en) * | 2019-03-04 | 2022-04-28 | King Abdullah University Of Science And Technology | Compositions and methods of targeted nucleic acid enrichment by loop adapter protection and exonuclease digestion |
CN111748611B (en) * | 2019-03-28 | 2021-02-19 | 深圳华大基因科技服务有限公司 | PCR primer and application thereof in DNA fragment connection |
KR102187795B1 (en) * | 2019-04-30 | 2020-12-08 | (주)디엑솜 | Preparing method of library for next generation sequencing using deoxyuridine |
KR102159008B1 (en) * | 2019-10-18 | 2020-09-23 | 고려대학교 산학협력단 | Self-priming and replicating hairpin adaptor for NGS library preparation and method for making NGS library using the same |
CN111893170B (en) * | 2020-08-07 | 2022-08-19 | 珠海舒桐医疗科技有限公司 | Method for detecting CRISPR-Cas off-target effect in whole genome range in vitro |
Citations (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5912148A (en) | 1994-08-19 | 1999-06-15 | Perkin-Elmer Corporation Applied Biosystems | Coupled amplification and ligation method |
US6007988A (en) | 1994-08-20 | 1999-12-28 | Medical Research Council | Binding proteins for recognition of DNA |
US6258568B1 (en) | 1996-12-23 | 2001-07-10 | Pyrosequencing Ab | Method of sequencing DNA based on the detection of the release of pyrophosphate and enzymatic nucleotide degradation |
US20020160940A1 (en) | 1999-01-12 | 2002-10-31 | Case Casey C. | Modulation of endogenous gene expression in cells |
US6503717B2 (en) | 1999-12-06 | 2003-01-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
US6511808B2 (en) | 2000-04-28 | 2003-01-28 | Sangamo Biosciences, Inc. | Methods for designing exogenous regulatory molecules |
US6818395B1 (en) | 1999-06-28 | 2004-11-16 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
WO2004099366A2 (en) | 2002-10-23 | 2004-11-18 | The General Hospital Corporation | Context sensitive parallel optimization of zinc finger dna binding domains |
US6833246B2 (en) | 1999-09-29 | 2004-12-21 | Solexa, Ltd. | Polynucleotide sequencing |
US6969488B2 (en) | 1998-05-22 | 2005-11-29 | Solexa, Inc. | System and apparatus for sequential processing of analytes |
US7115400B1 (en) | 1998-09-30 | 2006-10-03 | Solexa Ltd. | Methods of nucleic acid amplification and sequencing |
US20060292611A1 (en) * | 2005-06-06 | 2006-12-28 | Jan Berka | Paired end sequencing |
US7170050B2 (en) | 2004-09-17 | 2007-01-30 | Pacific Biosciences Of California, Inc. | Apparatus and methods for optical analysis of molecules |
US7169560B2 (en) | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
US7282337B1 (en) | 2006-04-14 | 2007-10-16 | Helicos Biosciences Corporation | Methods for increasing accuracy of nucleic acid sequencing |
US7302146B2 (en) | 2004-09-17 | 2007-11-27 | Pacific Biosciences Of California, Inc. | Apparatus and method for analysis of molecules |
US7329492B2 (en) | 2000-07-07 | 2008-02-12 | Visigen Biotechnologies, Inc. | Methods for real-time single molecule sequence determination |
US7482120B2 (en) | 2005-01-28 | 2009-01-27 | Helicos Biosciences Corporation | Methods and compositions for improving fidelity in a nucleic acid synthesis reaction |
US7501245B2 (en) | 1999-06-28 | 2009-03-10 | Helicos Biosciences Corp. | Methods and apparatuses for analyzing polynucleotide sequences |
US7803550B2 (en) | 2005-08-02 | 2010-09-28 | Rubicon Genomics, Inc. | Methods of producing nucleic acid molecules comprising stem loop oligonucleotides |
WO2011017293A2 (en) | 2009-08-03 | 2011-02-10 | The General Hospital Corporation | Engineering of zinc finger arrays by context-dependent assembly |
US8420319B2 (en) | 2008-04-30 | 2013-04-16 | Population Genetics Technologies Ltd | Asymmetric adapter library construction |
US20130274147A1 (en) | 2010-05-06 | 2013-10-17 | Ibis Biosciences, Inc. | Integrated sample preparation systems and stabilized enzyme mixtures |
US20130309668A1 (en) * | 2004-03-08 | 2013-11-21 | Rubicon Genomics, Inc. | Methods and compositions for generating and amplifying dna libraries for sensitive detection and analysis of dna methylation |
WO2014020137A1 (en) | 2012-08-02 | 2014-02-06 | Qiagen Gmbh | Recombinase mediated targeted dna enrichment for next generation sequencing |
US20140038831A1 (en) | 2012-08-01 | 2014-02-06 | Bernhard Suter | High throughput yeast two-hybrid screening method and reagent kit |
US20140162897A1 (en) | 2008-10-24 | 2014-06-12 | Illumina, Inc. | Transposon end compositions and methods for modifying nucleic acids |
US20140295557A1 (en) * | 2013-03-15 | 2014-10-02 | The General Hospital Corporation | Using Truncated Guide RNAs (tru-gRNAs) to Increase Specificity for RNA-Guided Genome Editing |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2336362B1 (en) | 2005-08-26 | 2018-09-19 | DuPont Nutrition Biosciences ApS | Use of crispr associated genes (cas) |
JP2009515896A (en) | 2005-11-11 | 2009-04-16 | ファイザー・インク | Combination therapy using immunomodulatory oligodeoxynucleotides |
HUE025412T2 (en) | 2007-03-02 | 2016-02-29 | Dupont Nutrition Biosci Aps | Cultures with improved phage resistance |
WO2009027978A1 (en) | 2007-08-30 | 2009-03-05 | Hadasit Medical Research Services & Development Ltd. | NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS |
US8546553B2 (en) | 2008-07-25 | 2013-10-01 | University Of Georgia Research Foundation, Inc. | Prokaryotic RNAi-like system and methods of use |
US8383345B2 (en) | 2008-09-12 | 2013-02-26 | University Of Washington | Sequence tag directed subassembly of short sequencing reads into long sequencing reads |
US20100076057A1 (en) | 2008-09-23 | 2010-03-25 | Northwestern University | TARGET DNA INTERFERENCE WITH crRNA |
US9404098B2 (en) | 2008-11-06 | 2016-08-02 | University Of Georgia Research Foundation, Inc. | Method for cleaving a target RNA using a Cas6 polypeptide |
ES2499032T3 (en) | 2008-12-12 | 2014-09-26 | Dupont Nutrition Biosciences Aps | Genetic group of Streptococcus thermophilus strains that have unique rheological properties for lactic fermentation |
JP5387839B2 (en) | 2009-09-04 | 2014-01-15 | アイシン・エィ・ダブリュ株式会社 | Navigation device, navigation method, and navigation program |
US9023769B2 (en) * | 2009-11-30 | 2015-05-05 | Complete Genomics, Inc. | cDNA library for nucleic acid sequencing |
WO2011086118A1 (en) | 2010-01-14 | 2011-07-21 | Deutsches Krebsforschungszentrum | In vivo determination of the lokalization of dna double-stand breaks and application thereof |
EP2534163B1 (en) | 2010-02-09 | 2015-11-04 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
US10087431B2 (en) | 2010-03-10 | 2018-10-02 | The Regents Of The University Of California | Methods of generating nucleic acid fragments |
DK2569425T3 (en) | 2010-05-10 | 2016-10-03 | Univ California | Endoribonuclease COMPOSITIONS AND METHODS OF USE THEREOF |
EP2638163B1 (en) | 2010-11-12 | 2017-05-17 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
WO2013078470A2 (en) | 2011-11-22 | 2013-05-30 | MOTIF, Active | Multiplex isolation of protein-associated nucleic acids |
CN102373288B (en) * | 2011-11-30 | 2013-12-11 | 盛司潼 | Method and kit for sequencing target areas |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
CN104603287B (en) | 2012-05-10 | 2018-01-19 | 通用医疗公司 | Method for determining nucleotide sequence |
GB2537000C (en) | 2012-05-25 | 2019-10-09 | Univ California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
WO2013191775A2 (en) | 2012-06-18 | 2013-12-27 | Nugen Technologies, Inc. | Compositions and methods for negative selection of non-desired nucleic acid sequences |
US20140024542A1 (en) | 2012-07-17 | 2014-01-23 | Counsyl, Inc. | Methods and compositions for enrichment of target polynucleotides |
WO2014018080A1 (en) | 2012-07-24 | 2014-01-30 | Natera, Inc. | Highly multiplex pcr methods and compositions |
WO2014071070A1 (en) * | 2012-11-01 | 2014-05-08 | Pacific Biosciences Of California, Inc. | Compositions and methods for selection of nucleic acids |
EP2914745B1 (en) * | 2012-11-05 | 2017-09-06 | Rubicon Genomics, Inc. | Barcoding nucleic acids |
PL2898075T3 (en) | 2012-12-12 | 2016-09-30 | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation | |
US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
PT2931898E (en) | 2012-12-12 | 2016-06-16 | Harvard College | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
DK3252160T3 (en) | 2012-12-12 | 2021-02-01 | Broad Inst Inc | SYSTEMS, METHODS AND COMPOSITIONS OF CRISPR-CAS SEQUENCE MANIPULATION COMPONENTS |
EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
EP3144390B1 (en) | 2012-12-12 | 2020-03-18 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
KR20150105633A (en) | 2012-12-12 | 2015-09-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
SG10201912328UA (en) | 2012-12-12 | 2020-02-27 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
AR093979A1 (en) | 2012-12-13 | 2015-07-01 | Dow Agrosciences Llc | DNA DETECTION METHODS FOR SITE SPECIFIC NUCLEASE ACTIVITY |
CN105142396A (en) | 2013-01-14 | 2015-12-09 | 重组股份有限公司 | Hornless livestock |
US20140212869A1 (en) | 2013-01-25 | 2014-07-31 | Agilent Technologies, Inc. | Nucleic Acid Proximity Assay Involving the Formation of a Three-way junction |
WO2014130955A1 (en) | 2013-02-25 | 2014-08-28 | Sangamo Biosciences, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
JP2016519652A (en) | 2013-03-14 | 2016-07-07 | カリブー・バイオサイエンシーズ・インコーポレイテッド | Nucleic acid targeting nucleic acid compositions and methods |
US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
AU2014248208C1 (en) | 2013-04-05 | 2023-04-27 | Corteva Agriscience Llc | Methods and compositions for integration of an exogenous sequence within the genome of plants |
ES2888250T3 (en) | 2013-04-16 | 2022-01-03 | Regeneron Pharma | Targeted modification of the rat genome |
CA2910427C (en) | 2013-05-10 | 2024-02-20 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
EP3022304B1 (en) | 2013-07-19 | 2018-12-26 | Larix Biosciences LLC | Methods and compositions for producing double allele knock outs |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
CA2930942A1 (en) * | 2013-11-18 | 2015-05-21 | Rubicon Genomics, Inc. | Degradable adaptors for background reduction |
CA3211550A1 (en) * | 2014-01-31 | 2015-08-06 | Integrated Dna Technologies, Inc. | Improved methods for processing dna substrates |
EP3158066B1 (en) | 2014-06-23 | 2021-05-12 | The General Hospital Corporation | Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq) |
JP6817215B2 (en) | 2015-03-03 | 2021-01-20 | ザ ジェネラル ホスピタル コーポレイション | Genetically engineered CRISPR-Cas9 nuclease with modified PAM specificity |
EP3341477B1 (en) | 2015-08-28 | 2022-03-23 | The General Hospital Corporation | Engineered crispr-cas9 nucleases |
US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
AU2016319110B2 (en) | 2015-09-11 | 2022-01-27 | The General Hospital Corporation | Full interrogation of nuclease DSBs and sequencing (FIND-seq) |
JP2018529353A (en) | 2015-09-30 | 2018-10-11 | ザ ジェネラル ホスピタル コーポレイション | Comprehensive in vitro reporting of cleavage events by sequencing (CIRCLE-seq) |
CN108699598B (en) | 2015-10-30 | 2022-11-15 | 新英格兰生物实验室公司 | Compositions and methods for analyzing modified nucleotides |
SG11201803646YA (en) | 2015-11-04 | 2018-05-30 | Atreca Inc | Combinatorial sets of nucleic acid barcodes for analysis of nucleic acids associated with single cells |
IL264565B2 (en) | 2016-08-03 | 2024-07-01 | Harvard College | Adenosine nucleobase editors and uses thereof |
WO2018052247A1 (en) | 2016-09-13 | 2018-03-22 | 주식회사 툴젠 | Method for identifying dna base editing by means of cytosine deaminase |
EP3630970A4 (en) | 2017-05-25 | 2020-12-30 | The General Hospital Corporation | Base editors with improved precision and specificity |
CN111278450B (en) | 2017-08-23 | 2024-04-09 | 通用医疗公司 | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
US11725228B2 (en) | 2017-10-11 | 2023-08-15 | The General Hospital Corporation | Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies |
AU2019256287A1 (en) | 2018-04-17 | 2020-11-12 | The General Hospital Corporation | Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents |
-
2016
- 2016-09-09 AU AU2016319110A patent/AU2016319110B2/en active Active
- 2016-09-09 CN CN201680065929.XA patent/CN108350453A/en active Pending
- 2016-09-09 KR KR1020187009641A patent/KR20180043369A/en unknown
- 2016-09-09 CA CA3000816A patent/CA3000816A1/en not_active Abandoned
- 2016-09-09 WO PCT/US2016/051097 patent/WO2017044843A1/en active Application Filing
- 2016-09-09 JP JP2018513347A patent/JP2018530536A/en active Pending
- 2016-09-09 EP EP16845183.9A patent/EP3347467B1/en active Active
- 2016-09-12 US US15/262,972 patent/US9988674B2/en active Active
-
2018
- 2018-03-07 IL IL257955A patent/IL257955A/en unknown
- 2018-05-31 US US15/994,939 patent/US11028429B2/en active Active
Patent Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5912148A (en) | 1994-08-19 | 1999-06-15 | Perkin-Elmer Corporation Applied Biosystems | Coupled amplification and ligation method |
US6130073A (en) | 1994-08-19 | 2000-10-10 | Perkin-Elmer Corp., Applied Biosystems Division | Coupled amplification and ligation method |
US6007988A (en) | 1994-08-20 | 1999-12-28 | Medical Research Council | Binding proteins for recognition of DNA |
US6013453A (en) | 1994-08-20 | 2000-01-11 | Medical Research Council | Binding proteins for recognition of DNA |
US6258568B1 (en) | 1996-12-23 | 2001-07-10 | Pyrosequencing Ab | Method of sequencing DNA based on the detection of the release of pyrophosphate and enzymatic nucleotide degradation |
US6969488B2 (en) | 1998-05-22 | 2005-11-29 | Solexa, Inc. | System and apparatus for sequential processing of analytes |
US7115400B1 (en) | 1998-09-30 | 2006-10-03 | Solexa Ltd. | Methods of nucleic acid amplification and sequencing |
US20020160940A1 (en) | 1999-01-12 | 2002-10-31 | Case Casey C. | Modulation of endogenous gene expression in cells |
US6818395B1 (en) | 1999-06-28 | 2004-11-16 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
US6911345B2 (en) | 1999-06-28 | 2005-06-28 | California Institute Of Technology | Methods and apparatus for analyzing polynucleotide sequences |
US7501245B2 (en) | 1999-06-28 | 2009-03-10 | Helicos Biosciences Corp. | Methods and apparatuses for analyzing polynucleotide sequences |
US6833246B2 (en) | 1999-09-29 | 2004-12-21 | Solexa, Ltd. | Polynucleotide sequencing |
US6503717B2 (en) | 1999-12-06 | 2003-01-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
US6511808B2 (en) | 2000-04-28 | 2003-01-28 | Sangamo Biosciences, Inc. | Methods for designing exogenous regulatory molecules |
US7329492B2 (en) | 2000-07-07 | 2008-02-12 | Visigen Biotechnologies, Inc. | Methods for real-time single molecule sequence determination |
WO2004099366A2 (en) | 2002-10-23 | 2004-11-18 | The General Hospital Corporation | Context sensitive parallel optimization of zinc finger dna binding domains |
US7169560B2 (en) | 2003-11-12 | 2007-01-30 | Helicos Biosciences Corporation | Short cycle methods for sequencing polynucleotides |
US20130309668A1 (en) * | 2004-03-08 | 2013-11-21 | Rubicon Genomics, Inc. | Methods and compositions for generating and amplifying dna libraries for sensitive detection and analysis of dna methylation |
US7302146B2 (en) | 2004-09-17 | 2007-11-27 | Pacific Biosciences Of California, Inc. | Apparatus and method for analysis of molecules |
US7313308B2 (en) | 2004-09-17 | 2007-12-25 | Pacific Biosciences Of California, Inc. | Optical analysis of molecules |
US7476503B2 (en) | 2004-09-17 | 2009-01-13 | Pacific Biosciences Of California, Inc. | Apparatus and method for performing nucleic acid analysis |
US7170050B2 (en) | 2004-09-17 | 2007-01-30 | Pacific Biosciences Of California, Inc. | Apparatus and methods for optical analysis of molecules |
US7482120B2 (en) | 2005-01-28 | 2009-01-27 | Helicos Biosciences Corporation | Methods and compositions for improving fidelity in a nucleic acid synthesis reaction |
US20060292611A1 (en) * | 2005-06-06 | 2006-12-28 | Jan Berka | Paired end sequencing |
US8399199B2 (en) | 2005-08-02 | 2013-03-19 | Rubicon Genomics | Use of stem-loop oligonucleotides in the preparation of nucleic acid molecules |
US8071312B2 (en) | 2005-08-02 | 2011-12-06 | Rubicon Genomics, Inc. | Methods for producing and using stem-loop oligonucleotides |
US7803550B2 (en) | 2005-08-02 | 2010-09-28 | Rubicon Genomics, Inc. | Methods of producing nucleic acid molecules comprising stem loop oligonucleotides |
US8728737B2 (en) | 2005-08-02 | 2014-05-20 | Rubicon Genomics, Inc. | Attaching a stem-loop oligonucleotide to a double stranded DNA molecule |
US7282337B1 (en) | 2006-04-14 | 2007-10-16 | Helicos Biosciences Corporation | Methods for increasing accuracy of nucleic acid sequencing |
US8420319B2 (en) | 2008-04-30 | 2013-04-16 | Population Genetics Technologies Ltd | Asymmetric adapter library construction |
US20140162897A1 (en) | 2008-10-24 | 2014-06-12 | Illumina, Inc. | Transposon end compositions and methods for modifying nucleic acids |
WO2011017293A2 (en) | 2009-08-03 | 2011-02-10 | The General Hospital Corporation | Engineering of zinc finger arrays by context-dependent assembly |
US20130274147A1 (en) | 2010-05-06 | 2013-10-17 | Ibis Biosciences, Inc. | Integrated sample preparation systems and stabilized enzyme mixtures |
US20140038831A1 (en) | 2012-08-01 | 2014-02-06 | Bernhard Suter | High throughput yeast two-hybrid screening method and reagent kit |
WO2014020137A1 (en) | 2012-08-02 | 2014-02-06 | Qiagen Gmbh | Recombinase mediated targeted dna enrichment for next generation sequencing |
US20140295557A1 (en) * | 2013-03-15 | 2014-10-02 | The General Hospital Corporation | Using Truncated Guide RNAs (tru-gRNAs) to Increase Specificity for RNA-Guided Genome Editing |
Non-Patent Citations (73)
Title |
---|
ARNOULD ET AL., JOURNAL OF MOLECULAR BIOLOGY, vol. 355, 2006, pages 443 - 58 |
ARNOULD ET AL., PROTEIN ENGINEERING DESIGN & SELECTION, vol. 24, 2011, pages 27 - 31 |
BAE ET AL., NAT. BIOTECHNOL., vol. 21, 2003, pages 275 - 280 |
BEERLI ET AL., NAT. BIOTECHNOL., vol. 20, 2002, pages 135 - 141 |
BERG, PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 99 |
BOGDANOVE ET AL., CURR OPIN PLANT BIOL, vol. 13, 2010, pages 394 - 401 |
BOGDANOVEVOYTAS, SCIENCE, vol. 333, 2011, pages 1843 - 1846 |
BOISSEL ET AL., NUCL. ACIDS RES., vol. 42, no. 4, 2014, pages 2591 - 2601 |
BOISSELSCHARENBERG, METHODS MOL BIOL., vol. 1239, 2015, pages 171 - 96 |
CARROLL ET AL., NAT. PROTOC., vol. 1, 2006, pages 1637 - 52 |
CARROLL, GENE THER., vol. 15, 2008, pages 1463 - 68 |
CATHOMEN, MOL. THER., vol. 16, 2008, pages 1200 - 07 |
CHOO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 11163 |
CHRISTIAN ET AL., GENETICS, vol. 186, 2010, pages 757 - 761 |
CLARK-CURTISSCURTISS ET AL.: "Methods in Enzymology", vol. 101, 1983, pages: 347 - 362 |
DICARLO ET AL., NUCLEIC ACIDS RES, 2013 |
ELROD-ERICKSON ET AL., STRUCTURE, vol. 6, 1998, pages 451 |
GAJ ET AL., TRENDS BIOTECHNOL., vol. 31, no. 7, July 2013 (2013-07-01), pages 397 - 405 |
GEISSLER ET AL., PLOS ONE, vol. 6, 2011, pages e19722 |
GNIRKE ET AL., NATURE BIOTECHNOLOGY, vol. 27, 2009, pages 182 - 189 |
GRATZ ET AL., GENETICS, vol. 194, no. 4, 2013, pages 1029 - 35 |
GRIZOT ET AL., NUCLEIC ACIDS RESEARCH, vol. 38, 2010, pages 2006 - 18 |
HOCKEMEYE ET AL., NAT BIOTECHNOL, vol. 29, 2011, pages 699 - 700 |
HORVATH ET AL., SCIENCE, vol. 327, 2010, pages 167 - 170 |
HWANG ET AL., NAT BIOTECHNOL, vol. 31, 2013, pages 230 - 232 |
ISALAN ET AL., NAT. BIOTECHNOL., vol. 19, 2001, pages 656 - 660 |
ISLAM ET AL., NATURE METHODS, vol. 11, 2014, pages 163 - 166 |
JAMIESON ET AL., BIOCHEMISTRY, vol. 33, 1994, pages 5689 - 1264 |
JIANG ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 32230 - 32239 |
JINEK ET AL., ELIFE, vol. 2, 2013, pages e00471 |
JINEK ET AL., SCIENCE, vol. 337, 2012, pages 816 - 821 |
JOUNG ET AL., NAT. METHODS, vol. 7, 2010, pages 91 - 92 |
KARLSSON ET AL., GENOMICS, vol. 105, no. 3, March 2015 (2015-03-01), pages 150 - 8 |
KIM ET AL., GENOME RES., vol. 19, 2009, pages 1279 - 88 |
KIM ET AL., NAT METHODS, vol. 12, no. 3, March 2015 (2015-03-01), pages 237 - 43 |
KIVIOJA ET AL., NATURE METHODS, vol. 9, 2012, pages 72 - 74 |
KLUG, GENE, vol. 135, 1993, pages 83 |
KRIEGLER, GENE TRANSFER AND EXPRESSION: A LABORATORY MANUAL, 2006 |
LEE ET AL., SCIENCE, vol. 245, 1989, pages 635 |
LINDHAL ET AL., J. BIOL. CHEM., vol. 252, 1977, pages 3286 - 3294 |
LINDHAL, ANNU. REV. BIOCHEM., vol. 51, 1982, pages 61 - 64 |
LIU ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 3850 - 56 |
MACLEAN ET AL., NATURE REV. MICROBIOL., vol. 7, 2009, pages 287 - 296 |
MAEDER ET AL., MOL. CELL, vol. 31, 2008, pages 294 - 301 |
MALI ET AL., SCIENCE, vol. 339, 2013, pages 823 - 826 |
MANDELL ET AL., NUCLEIC ACIDS RES., vol. 34, 2006, pages 516 - 523 |
METZKER, NAT REV GENET, vol. 11, no. 1, 2010, pages 31 - 46 |
METZKER, NATURE REVIEWS GENETICS, vol. 11, 2010, pages 31 - 46 |
MILLER ET AL., EMBO J., vol. 4, 1985, pages 1609 |
MORBITZER ET AL., T. PROC NATL ACAD SCI U S A, vol. 107, 2010, pages 21617 - 21622 |
MORRISON, J. BACTERIOL., vol. 132, 1977, pages 349 - 351 |
MOSCOUBOGDANOVE, SCIENCE, vol. 326, 2009, pages 1501 - 1512 |
MUSSOLINO ET AL., NUCLEIC ACIDS RES, vol. 39, 2011, pages 6315 - 6325 |
PAVLETICH ET AL., SCIENCE, vol. 252, 1991, pages 809 |
RAMIREZ ET AL., NAT. METHODS, vol. 5, 2008, pages 374 - 375 |
REBAR ET AL., SCIENCE, vol. 263, 1994, pages 671 |
REYON ET AL., NATURE BIOTECHNOLOGY, vol. 30, 2012, pages 460 - 465 |
SCHOLZEBOCH, J. CURR OPIN MICROBIOL, 2011 |
See also references of EP3347467A4 |
SEGAL ET AL., BIOCHEMISTRY, vol. 42, 2003, pages 2137 - 48 |
SHAPE-SEQ, LUCKS ET AL., PROC NATL ACAD SCI U S A, vol. 108, 2011, pages 11063 - 11068 |
SHEN ET AL., CELL RES, 2013 |
SILVA, G. ET AL., CURRENT GENE THERAPY, vol. 11, 2011, pages 11 - 27 |
STODDARD, Q., REV. BIOPHYS., vol. 38, 2005, pages 49 |
TERNS ET AL., CURR OPIN MICROBIOL, vol. 14, 2011, pages 321 - 327 |
TSAI ET AL., NAT BIOTECHNOL., 2015 |
TSAI ET AL., NAT BIOTECHNOL., vol. 33, no. 2, February 2015 (2015-02-01), pages 187 - 97 |
VOELKERDING ET AL., CLINICAL CHEM., vol. 55, 2009, pages 641 - 658 |
VOELKERDING ET AL., CLINICAL CHEMISTRY, vol. 55, no. 4, 2009, pages 641 - 658 |
WANG ET AL., CELL, vol. 153, 2013, pages 910 - 918 |
WIEDENHEFT ET AL., NATURE, vol. 482, 2012, pages 331 - 338 |
WU ET AL., CELL. MOL. LIFE SCI., vol. 64, 2007, pages 2933 - 44 |
WU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 344 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3500669A4 (en) * | 2016-08-16 | 2020-01-22 | The Regents of the University of California | Method for finding low abundance sequences by hybridization (flash) |
US11046995B2 (en) | 2016-08-16 | 2021-06-29 | The Regents Of The University Of California | Method for finding low abundance sequences by hybridization (FLASH) |
WO2019224560A1 (en) * | 2018-05-24 | 2019-11-28 | Oxford Nanopore Technologies Limited | Method |
US20210198732A1 (en) * | 2018-05-24 | 2021-07-01 | Oxford Nanopore Technologies Limited | Method |
JP2021523704A (en) * | 2018-05-24 | 2021-09-09 | オックスフォード ナノポール テクノロジーズ リミテッド | Method |
JP7365363B2 (en) | 2018-05-24 | 2023-10-19 | オックスフォード ナノポール テクノロジーズ ピーエルシー | Method |
CN108753923A (en) * | 2018-06-04 | 2018-11-06 | 广州微芯生物科技有限公司 | A kind of method building the sequencing library that methylates and corresponding joint sequence and kit |
CN108753922A (en) * | 2018-06-04 | 2018-11-06 | 广州微芯生物科技有限公司 | A kind of method building transcript profile sequencing library and corresponding joint sequence and kit |
CN108753921A (en) * | 2018-06-04 | 2018-11-06 | 广州微芯生物科技有限公司 | A kind of method building gene order-checking library and corresponding joint sequence and kit |
Also Published As
Publication number | Publication date |
---|---|
CA3000816A1 (en) | 2017-03-16 |
EP3347467A1 (en) | 2018-07-18 |
EP3347467B1 (en) | 2021-06-23 |
IL257955A (en) | 2018-05-31 |
JP2018530536A (en) | 2018-10-18 |
US20170073747A1 (en) | 2017-03-16 |
AU2016319110B2 (en) | 2022-01-27 |
US9988674B2 (en) | 2018-06-05 |
EP3347467A4 (en) | 2019-02-20 |
CN108350453A (en) | 2018-07-31 |
KR20180043369A (en) | 2018-04-27 |
US20180265920A1 (en) | 2018-09-20 |
US11028429B2 (en) | 2021-06-08 |
AU2016319110A1 (en) | 2018-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016319110B2 (en) | Full interrogation of nuclease DSBs and sequencing (FIND-seq) | |
AU2021212165B2 (en) | Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq) | |
US10738303B2 (en) | Comprehensive in vitro reporting of cleavage events by sequencing (CIRCLE-seq) | |
EP3812472B1 (en) | A truly unbiased in vitro assay to profile off-target activity of one or more target-specific programmable nucleases in cells (abnoba-seq) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16845183 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 257955 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2018513347 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 3000816 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20187009641 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016845183 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016319110 Country of ref document: AU Date of ref document: 20160909 Kind code of ref document: A |